UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

Clinical Trial Simulation: A Review

Clinical pharmacology and therapeutics, 2010-08, Vol.88 (2), p.166-182

2010

Volltextzugriff (PDF)

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-07, Vol.23 (4), p.528-537

2017

Volltextzugriff (PDF)

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Trends in pharmacological sciences (Regular ed.), 2008-04, Vol.29 (4), p.186-191

2008

Volltextzugriff (PDF)

Point-of-care testing in out-of-hospital cardiac arrest: a retrospective analysis of relevance and consequences

Scandinavian journal of trauma, resuscitation and emergency medicine, 2021-08, Vol.29 (1), p.128-128, Article 128

2021

Volltextzugriff (PDF)

Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction

Annals of oncology, 2019-07, Vol.30, p.iv90-iv90

2019

Volltextzugriff (PDF)

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling

British journal of pharmacology, 2014-11, Vol.171 (22), p.5076-5092

2014

Volltextzugriff (PDF)

Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S204-S205

2017

Volltextzugriff (PDF)

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

British journal of pharmacology, 2013-08, Vol.169 (7), p.1510-1524

2013

Volltextzugriff (PDF)

Response to "Validation and Assessment of Predictive Performance in Simulation Models of Clinical Trials"

Clinical pharmacology and therapeutics, 2011-04, Vol.89 (4), p.488-488

2011

Volltextzugriff (PDF)

Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs

Journal of veterinary pharmacology and therapeutics, 2013-04, Vol.36 (2), p.174-180

2013

Volltextzugriff (PDF)

Verification of reactive systems via instantiation of Parameterised Boolean Equation Systems

Information and computation, 2011-04, Vol.209 (4), p.637-663

2011

Volltextzugriff (PDF)

Estimation of Systemic Toxicity of Acrylamide by Integration of in Vitro Toxicity Data with Kinetic Simulations

Toxicology and applied pharmacology, 1999-08, Vol.158 (3), p.261-268

1999

Volltextzugriff (PDF)

Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models

European journal of cancer (1990), 2022-10, Vol.174, p.S101-S101

2022

Volltextzugriff (PDF)

Guideline on anterior cruciate ligament injury

Acta orthopaedica, 2012-08, Vol.83 (4), p.379-386

2012

Volltextzugriff (PDF)

Guideline on anterior cruciate ligament injury: A multidisciplinary review by the Dutch Orthopaedic Association

Acta orthopaedica, 2012-08, Vol.83 (4), p.379-386

2012

Volltextzugriff (PDF)

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

The Journal of biological chemistry, 2012-11, Vol.287 (49), p.41245-41257

2012

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

Toxicology and applied pharmacology, 2000-02, Vol.162 (3), p.177-188

2000

Volltextzugriff (PDF)

A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat

Journal of pharmacokinetics and pharmacodynamics, 2011-12, Vol.38 (6), p.697-711

2011

Volltextzugriff (PDF)

A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

European urology, 2023-02, Vol.83, p.S1709-S1710

2023

Volltextzugriff (PDF)

Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

European urology, 2023-02, Vol.83, p.S1709-S1710

2023

Volltextzugriff (PDF)

PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin

Clinical pharmacology and therapeutics, 2004-02, Vol.75 (2), p.P80-P80

2004

Volltextzugriff (PDF)

An integrated evaluation of phase 1 data including exposure-response analysis shows vilaprisan does not delay cardiac repolarization

Fertility and sterility, 2018-09, Vol.110 (4), p.e139-e139

2018

Volltextzugriff (PDF)

A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling

Pharmaceutical research, 2000-12, Vol.17 (12), p.1516-1525

2000

Volltextzugriff (PDF)

Abstract P1-16-03: An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-16-03

2018

Volltextzugriff (PDF)

THU-067 - Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S204-S205

2017

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(129)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Trial Simulation: A Review

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Point-of-care testing in out-of-hospital cardiac arrest: a retrospective analysis of relevance and consequences

Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling

Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

Response to "Validation and Assessment of Predictive Performance in Simulation Models of Clinical Trials"

Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs

Verification of reactive systems via instantiation of Parameterised Boolean Equation Systems

Estimation of Systemic Toxicity of Acrylamide by Integration of in Vitro Toxicity Data with Kinetic Simulations

Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models

Guideline on anterior cruciate ligament injury

Guideline on anterior cruciate ligament injury: A multidisciplinary review by the Dutch Orthopaedic Association

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat

A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin

An integrated evaluation of phase 1 data including exposure-response analysis shows vilaprisan does not delay cardiac repolarization

A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling

Abstract P1-16-03: An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup

THU-067 - Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Suchergebnisse filtern